Fulgent Genetics, Inc. (FLGT)

CIK 0001674930 · Healthcare · Diagnostics and Research

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q2-2026 8-K (2026-07-30) · 99.1 · 99.2
Q1-2026 8-K (2026-05-01) · 99.1 · 99.2
Latest FY-2025 8-K (2026-02-27) · 99.1 · 99.2
Q3-2025 8-K (2025-11-07) · 99.1 · 99.2
Q2-2025 8-K (2025-08-01) · 99.1 · 99.2
Q1-2025 8-K (2025-05-02) · 99.1 · 99.2
FY-2024 8-K (2025-02-28) · 99.1 · 99.2
Q3-2024 8-K (2024-11-08) · 99.1 · 99.2
Q2-2024 8-K (2024-08-02) · 99.1 · 99.2
Q1-2024 8-K (2024-05-03) · 99.1 · 99.2
FY-2023 8-K (2024-02-28)
Q3-2023 8-K (2023-11-03) · 99.1 · 99.2

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Document and Entity Information
Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Consolidated Statements of Operations
Condensed Consolidated Statements of Comprehensive Loss (unaudited)
—
Consolidated Statements of Comprehensive Income (loss)
Consolidated Statements of Stockholders' Equity
Consolidated Statements of Stockholders' Equity (P)
Consolidated Statements of Cash Flows
Notes
Business Combinations
Cybersecurity Risk Management, Strategy, and Governance
—
Debt, Commitments and Contingencies
Equity and Debt Securities
Equity-based Compensation
Fair Value Measurements
Fixed Assets
Goodwill and Acquisition-related Intangibles
—
Goodwill and Intangible Assets
Income (loss) Per Share
Income Taxes
Insider Trading Arrangements
Leases
Loss Per Share
—
Other Significant Balance Sheet Accounts
Overview and Basis of Presentation
Pay Vs Performance Disclosure
Related Parties
—
Related Party
Reportable Segment and Geographic Information
Reporting Segment and Geographic Information
—
Retirement Plans
Stock Repurchase Program
Stockholders' Equity
—
Subsequent Event
Summary of Significant Accounting Policies